Panel Discussion: Discovering the Risk: Benefit Ratio of AAV Gene Therapies & Life Limiting Indications

Time: 11:30 am
day: Day One


• Understanding the difference in adverse event tolerance between the different target populations

• Highlighting the balance between the risk associated with AAV gene therapy and the severity and life threatening capacity of the patient's disease

• Curating individual risk: benefit ratios for individual patients to understand the need for the AAV gene therapy treatment